Table 3

Impact of positive status for 14-3-3η ≥0.50 ng/mL (High-14-3-3η), positive rheumatoid factor (RF) and positive anti-CCP2 (ACPA) on prediction of rapid erosive progression (REP; ≥5 erosion units between two successive visits) according to normal (≤8.0 mg/L) or high C-reactive protein (High-CRP) at a given visit

VisitsREP (ΔErosions ≥5 between 2 visits)
Totaln (%)RR (95% CI)P value
Normal CRP (≤8.0 mg/L)
Individual variables
 High 14-3-3η45330 (6.6)1.15 (0.72–1.85)0.5627
 ACPA positive46840 (8.5)2.51 (1.59–3.98)<0.0001
 RF positive48146 (9.6)2.75 (1.70–4.47)<0.0001
RF, ACPA(n=1284)
 Both negative71319 (2.7)1
 One positive25120 (8)2.97 (1.65–5.35)0.0003
 Both positive32029 (9.1)3.48 (1.99–6.10)<0.0001
14-3-3η, RF(n=1383)
 Both negative72131 (4.3)1
 One positive40318 (4.5)1.15 (0.63–2.09)0.6497
 Both positive25929 (11.2)2.37 (1.35–4.17)0.0026
14-3-3η, ACPA(n=1238)
 Both negative59321 (3.5)1
 One positive43530 (6.9)1.86 (1.14–3.05)0.0138
 Both positive21017 (8.1)2.21 (1.18–4.15)0.0130
14-3-3η, RF, ACPA(n=1233)
 All negative53718 (3.4)1
 One positive29815 (5)1.52 (0.81–2.84)0.1922
 Two positive22618 (8)2.38 (1.26–4.50)0.0076
 All positive17217 (9.9)2.93 (1.54–5.57)0.0011
High CRP (˃8.0 mg/L)
Individual variables
 High 14-3-3η24159 (24.5)2.23 (1.54–3.22)<0.0001
 ACPA positive25963 (24.3)2.52 (1.60–3.97)<0.0001
 RF positive28169 (24.6)2.43 (1.57–3.75)<0.0001
RF, ACPA(n=654)
 Both negative34626 (7.5)1
 One positive10215 (14.7)1.85 (0.95–3.59)0.0703
 Both positive20656 (27.2)3.22 (1.96–5.27)<0.0001
14-3-3η, RF(n=700)
 Both negative34930 (8.6)1
 One positive19026 (13.7)1.8 (1.12–2.9)0.0154
 Both positive16151 (31.7)3.52 (2.2–5.64)<0.0001
14-3-3η, ACPA(n=642)
 Both negative31023 (7.4)1
 One positive19129 (15.2)2.18 (1.31–3.65)0.0029
 Both positive14144 (31.2)3.93 (2.30–6.73)<0.0001
14-3-3η, RF, ACPA(n=641)
 All negative28522 (7.7)1
 One positive1137 (6.2)1.14 (0.58–2.24)0.7084
 Two positive12127 (22.3)3.18 (1.71–5.90)0.0003
 All positive12240 (32.8)4.31 (2.46–7.56)<0.0001